Solicitar Cotización
Grupo Médico Kingphar

Novedades

06/10 2026

Tabla de contenidos

Incoming Quality Inspection (IQI) for Medical Consumables: Complete Guide
Procurement Quality · IQI Guide

Incoming Quality Inspection
for Medical Consumables
A Procurement Quality Gate

A supplier's Certificate of Analysis confirms what left the factory — not what arrived at the receiving dock. Incoming Quality Inspection (IQI) is the buyer's last verification point before medical consumables enter hospital inventory, clinical use, or further distribution.

AQL Sampling by Risk Class Product-Specific Checklists Sterile Barrier Verification ISO 13485 / FDA 21 CFR 820 NCR → CAPA Workflow Requisitos de Documentación
A
Albar
Auditor de Contenido y Operaciones de Contenido · Kingphar Medical
Sampling Standard
ISO 2859
Attributes inspection
Critical Defect AQL
0.065%
Zero-tolerance target
ISO 13485 Clause
7.4.3
Purchased product verification
FDA Reference
§820.80
Receiving acceptance
Sección 01

Why Incoming Inspection Is the Buyer's Last Line of Defense

Medical consumables travel thousands of kilometers between the manufacturer's clean room and the hospital's central supply. During that journey, products face temperature fluctuation, humidity exposure, physical impact, and handling by multiple logistics intermediaries. A supplier's Certificate of Analysis (CoA) and batch release records confirm product quality at the point of manufacture — not at the point of receipt.

Incoming Quality Inspection bridges this gap. IQI — also called incoming quality control (IQC) or receiving inspection — is the systematic process of evaluating delivered medical consumables against purchase specifications before releasing them into inventory or clinical use. Three categories of defects are only detectable at the receiving stage:

Transit-induced damage. Carton crush, moisture ingress through compromised corrugated packaging, and pallet shift during container loading can damage products without affecting external shipping labels. Gauze swabs compressed beyond specification may show reduced absorbency. Bandage rolls stored in high-humidity containers can develop mold on cotton substrates.

Sterile barrier compromise. Peelable Tyvek pouches and heat-sealed sterilization packaging can develop micro-perforations from vibration during ocean freight. These failures are invisible without deliberate visual inspection under adequate lighting. A compromised sterile barrier renders the product unsuitable for clinical use — regardless of what the manufacturer's sterility test certificate states.

Labeling and documentation mismatches. Mixed lots within a single shipment, incorrect expiry date labels applied during secondary packaging, and missing regulatory markings (CE, lot number, manufacturer details) are common issues that only systematic receiving inspection catches before products reach the ward.

Sección 02

Regulatory Framework: What FDA, ISO 13485, and SFDA Require

Incoming quality inspection is not a best practice recommendation — it is a regulatory requirement across all major medical device markets. The following standards establish the legal basis for IQI programs.

FDA 21 CFR 820.80 — Receiving Acceptance Activities

Under the FDA Quality System Regulation (QSR), Section 820.80(b) requires that each manufacturer establish and maintain procedures for acceptance of incoming product. These procedures must ensure that incoming product is not used or processed until it is verified as conforming to specified requirements, or the receipt is otherwise authorized by a designated procedure. The regulation requires documented acceptance records that demonstrate conformance to defined acceptance criteria.

For medical consumable distributors importing into the US market, this means every received lot must undergo documented verification activities before being released for sale or distribution. FDA inspectors routinely review receiving inspection records during facility audits.

ISO 13485 Clause 7.4.3 — Verification of Purchased Product

ISO 13485:2016 Clause 7.4.3 requires organizations to "establish and implement the inspection or other activities necessary for ensuring that purchased product meets specified purchase requirements." The standard mandates documented procedures, defined acceptance criteria based on supplier risk evaluation, and maintenance of verification records.

Clause 7.4.3 explicitly connects incoming inspection to the purchasing process: the acceptance criteria used at receiving must trace back to the specifications defined in the purchase order and any applicable quality agreements with the supplier. Records of these verification activities must be maintained as required by Clause 4.2.5 (Control of Records).

SFDA Import Inspection Expectations

For medical consumables imported into Saudi Arabia, SFDA guidance on shipment requirements establishes that importers must verify products against manufacturer specifications upon receipt. SFDA emphasizes storage and transportation condition verification — particularly for temperature-sensitive products, which must arrive with activated data logger evidence demonstrating continuous cold chain compliance from the point of shipment. Products failing to meet SFDA labeling requirements (Arabic language labeling, registration number, local agent details) must be quarantined and corrected before distribution.

Sección 03

AQL Selection Matrix for Medical Consumables by Risk Class

Acceptance Quality Limit (AQL) defines the maximum percentage of defective items considered acceptable in a production lot. AQL-based sampling plans — governed by ISO 2859-1 (equivalent to ANSI/ASQ Z1.4) — allow procurement teams to make statistically valid accept/reject decisions without inspecting every unit. The key decision is which AQL level to apply to each defect category.

Medical device industry practice classifies defects into three severity levels, each with a corresponding AQL target:

Defect ClassDefinitionAQLMedical Consumable Examples
CríticoCould cause patient harm, render the product unsafe for use, or violate regulatory requirements0 – 0.065%Compromised sterile barrier; missing or non-functional X-ray detectable marker; wrong product in packaging; contamination
PrincipalProduct fails to meet primary functional specification but does not create direct patient safety risk1.0%Gauze mesh count outside tolerance; bandage elasticity below specification; dressing absorbency under minimum; dimensional non-conformance exceeding ±5%
MinorCosmetic imperfection or non-critical deviation that does not affect function or safety2.5%Minor print misalignment on packaging; slight color variation; non-critical labeling font size deviation; minor fold irregularity
How to read the AQL table with ISO 2859-1: For a lot of 10,000 gauze swab packets at General Inspection Level II, ISO 2859-1 assigns sample size code letter "L" (200 units). At AQL 1.0% for major defects, the acceptance number (Ac) is 5 and the rejection number (Re) is 6. This means: inspect 200 randomly selected packets — if 5 or fewer show major defects, accept the lot; if 6 or more show major defects, reject the entire lot. Critical defects at AQL 0.065% effectively require zero defects found in the sample for lot acceptance.

AQL by Product Category

ProductoCritical AQLMajor AQLMinor AQLKey Critical Defects to Monitor
Gauze swabs (sterile)0.065%1.0%2.5%Sterile breach, foreign particles, mesh count deviation >2 threads
Gauze swabs (non-sterile)0.065%1.5%4.0%Foreign particles, wrong ply count, contamination
Crepe/elastic bandages0.065%1.0%2.5%Elasticity failure, clip/fastener missing, width >±3mm
Surgical drapes (sterile)0.065%0.65%1.5%Sterile breach, adhesive zone failure, fenestration misalignment
Wound dressings (sterile)0.065%0.65%1.5%Sterile breach, absorbent pad detachment, backing delamination
Lap sponges (X-ray detectable)0.065%0.65%1.5%X-ray marker absent/non-functional, thread count deviation, loop failure
Botiquines de primeros auxilios0.065%1.0%2.5%Missing contents vs. packing list, expired components, case damage
Sección 04

Product-Specific IQI Checklist

General-purpose incoming inspection checklists fail medical consumable procurement because they lack product-specific inspection criteria. The following checklists provide the exact parameters that receiving inspectors should verify for each product category.

Gauze Swabs & Rolls

ParámetroSpecification to VerifyMétodo de pruebaAccept/Reject Criteria
Mesh countPurchase order specification (e.g., 19×15, 20×12, 24×20 threads/inch)Thread count loupe (10× magnification), count threads in 1-inch square±1 thread from specification = accept; ±2+ = major defect
Conteo de capasAs specified (8-ply, 12-ply, 16-ply)Unfold one sample unit, count layersExact match required; deviation = major defect
DimensionesNominal size ±3% (e.g., 10×10 cm ±3mm)Steel ruler or calibrated tapeWithin ±3% = accept; beyond = major defect
AbsorbenciaPer EN 14079 or USP monograph minimumWeigh dry → immerse in saline → weigh wet (sink test)Below specification minimum = major defect
PelusasLow lint / lint-free as specifiedRub test: fold and rub 10 strokes on dark surface, visual assessmentExcessive fiber release = major defect
Integridad del embalajeNo tears, moisture, seal breachesVisual inspection, 100% of outer packagingAny breach on sterile product = critical defect
EtiquetadoLot number, expiry, size, ply, manufacturer, CE/regulatory marksVisual comparison against purchase orderMissing regulatory mark = critical; other = minor

Bandages (Crepe, Elastic, Conforming)

ParámetroSpecification to VerifyMétodo de pruebaAccept/Reject Criteria
AnchoNominal ±3mm (e.g., 10 cm ±3mm)Calibrated ruler at 3 points along rollBeyond ±3mm = major defect
Stretched lengthMinimum stretched length per specificationExtend roll along measuring tape with standardized tensionBelow minimum = major defect
Elasticity recoveryPer product specification (e.g., crepe ≥90% recovery after 3 stretches)Stretch to 150%, release, measure recovered lengthBelow specification = major defect
Clip/fastener presenceAs specified on purchase orderVisual inspection of sampled unitsMissing = major defect
Roll windingUniform, no telescopingInspección visualSevere telescoping = major; slight = minor
Packaging/labelingComplete, legible, regulatory compliantInspección visualAs per gauze criteria above

Wound Dressings (Foam, Island, Transparent Film)

ParámetroSpecification to VerifyMétodo de pruebaAccept/Reject Criteria
Sterile pouch integrityNo punctures, delamination, or incomplete sealsVisual inspection + gentle squeeze test for peel pouchAny compromise = critical defect
Indicador químicoColor change confirms sterilization processingVisual comparison against reference (unexposed indicator)No color change or ambiguous = critical defect
Adhesive zoneUniform coverage, no dry spots, release liner intactPeel release liner on 1 sample unit, inspect adhesive distributionAdhesive void >10% of border area = major defect
Almohadilla absorbenteCentered within dressing, correct thicknessVisual and tactile inspection through packaging (non-sterile) or on opened samplePad misaligned >3mm = major; detached = critical
DimensionesNominal ±5% per product specificationRuler measurement on opened sampleBeyond ±5% = major defect
Lot/expiry/labelingAs per regulatory requirementsVisualStandard labeling criteria

Surgical Consumables (Lap Sponges, Surgical Drapes)

ParámetroSpecification to VerifyMétodo de pruebaAccept/Reject Criteria
X-ray detectable markerPresent, securely attached, radiopaqueVisual for presence; handheld metal detector or sample X-ray for radiopacity (if facility available)Absent or non-functional = critical defect
Thread/tape countPer specification (e.g., 28×24 for lap sponge)Thread count loupeDeviation >2 threads = major defect
Embalaje estérilDouble-wrapped or pouch intactVisual + squeeze testAny breach = critical defect
Piece count per packExact match to label (e.g., 5/pack)Open and count 1 sample packMismatch = critical defect (surgical count safety)
Loop/tail presenceFunctional loop or tail for retrievalVisual + gentle pull testMissing or detached = critical defect
Sección 05

Sterile Barrier Verification at Receiving

Sterile medical consumables represent the highest-risk category for incoming inspection because a single undetected sterile barrier failure can result in patient infection. The following verification protocol applies to all sterile products before they are released from receiving quarantine.

Step 1: Outer carton assessment (100% of cartons). Before opening any carton, inspect all outer shipping containers for water staining, crush damage, puncture holes, evidence of repacking, and broken tamper-evident seals. Any carton showing moisture intrusion should have its entire contents quarantined pending inner packaging inspection. Photograph damaged cartons before opening as documentation for potential supplier claims.

Step 2: Inner packaging visual inspection (per AQL sampling plan). For the selected sample quantity, inspect each individual sterile pouch or wrap under adequate lighting (minimum 500 lux, per ISO 3006 recommendations). Check for seal continuity on all edges, Tyvek or paper lid integrity (no punctures, tears, or abrasion), absence of channel defects along heat-sealed edges, and correct orientation of the peel-open tab.

Step 3: Chemical indicator verification. Confirm that external chemical indicators on sterile packaging show the expected color change corresponding to the sterilization method (ETO or gamma irradiation). An unexposed or partially exposed indicator suggests the product was not sterilized or the indicator was applied after sterilization — both are critical non-conformances requiring immediate lot quarantine and supplier notification.

Step 4: Temperature data logger review (if applicable). For shipments requiring temperature-controlled transport — either by product specification or by SFDA import requirements — retrieve the data logger from the shipping container and download the temperature record. Verify that temperature remained within the manufacturer's specified range throughout transit. Any excursion beyond the specified range must be documented and evaluated against the product's stability data before making an acceptance decision.

Step 5: Expiry date and shelf life verification. Confirm that remaining shelf life meets the facility's minimum acceptance threshold. Many hospital procurement policies require a minimum of 75% remaining shelf life at the time of receipt. For SFDA-regulated imports into Saudi Arabia, specific minimum remaining shelf life requirements apply at the point of customs clearance.

Sección 06

Non-Conformance Workflow: NCR to Supplier CAPA

When incoming inspection identifies a defect that exceeds the AQL acceptance threshold, a structured non-conformance workflow ensures proper product disposition, supplier accountability, and preventive action. The following process aligns with ISO 13485 Clause 8.3 (Control of Nonconforming Product) and FDA 21 CFR 820.90.

1. Quarantine. Immediately move the rejected lot (or the specific non-conforming units if the lot is partially accepted) to a physically separated, clearly labeled quarantine area. Quarantined products must not be accessible for picking, distribution, or clinical use. Apply a "HOLD — Do Not Use" label or tag with the date, inspector name, and NCR reference number.

2. Issue Non-Conformance Report (NCR). Document the following in the NCR: supplier name and lot number, purchase order reference, quantity received and quantity inspected, defect description with defect classification (critical/major/minor), photographic evidence, reference to the applicable specification or standard, and the inspector's recommendation for disposition.

3. Defect classification and disposition decision. The Quality Manager (or designated authority) reviews the NCR and determines disposition based on defect severity:

DispositionWhen AppliedAuthorization Required
Return to supplierCritical defect or major defect affecting entire lotQuality Manager + Procurement
Use-as-is (concession)Minor defect only; documented justification that function and safety are unaffectedQuality Manager written approval; not applicable to critical defects
Rework/relabelLabeling error correctable at receiving (e.g., missing secondary label)Quality Manager + Regulatory, if applicable
ScrapContaminated or damaged beyond recoveryQuality Manager

4. Supplier notification and CAPA request. Forward the NCR to the supplier within 48 hours of detection. Request a formal Corrective and Preventive Action (CAPA) response within a defined timeline — typically 10 to 15 business days for major defects, 30 days for minor defects. The CAPA should include root cause analysis (using 5-Why, fishbone diagram, or equivalent methodology), immediate corrective actions already taken, and preventive actions to avoid recurrence with implementation timeline.

5. CAPA verification and closure. Evaluate the supplier's CAPA response for adequacy. Verify that corrective actions are implemented by reviewing the next 2–3 shipments against the same inspection criteria. Close the CAPA only when subsequent shipments demonstrate sustained compliance. Update the supplier quality scorecard with the non-conformance event and CAPA outcome.

Supplier quality impact: Recurring non-conformances should trigger escalated actions. Three major NCRs within 12 months for the same defect type typically justify requiring the supplier to submit pre-shipment inspection data for a defined probationary period, or conducting an on-site supplier audit. For guidance on structuring supplier audits, refer to the Kingphar Medical Consumable Supplier Audit Checklist.
Sección 07

IQI Documentation and Record Retention

Incoming inspection generates critical quality records that serve three purposes: regulatory compliance during audits, traceability in the event of a product recall, and supplier performance measurement over time.

Required records per inspection event: Inspection date and inspector identification, purchase order number and supplier lot/batch number, sample size and sampling plan reference (ISO 2859-1 code letter and AQL), inspection results by parameter (pass/fail for each checked attribute), accept/reject decision for the lot, and disposition record for any non-conforming product.

Record retention period. ISO 13485 requires quality records to be retained for at least the lifetime of the medical device or as specified by applicable regulatory requirements — whichever is longer. For medical consumables with a typical 3–5 year shelf life, a minimum record retention period of 5 years from the date of manufacture (or 2 years after the expiry date, whichever is later) is common practice. FDA-regulated facilities should retain records for the design and expected life of the device, with a minimum of 2 years from release date.

Traceability requirement. Every accepted lot must be traceable from receiving inspection records through to the distribution or clinical use record. This forward traceability enables field safety corrective actions (recalls) when a quality issue is discovered post-distribution. At minimum, the lot number, acceptance date, quantity accepted, and storage location must link between receiving inspection records and inventory management systems.

Electronic records. Facilities using electronic quality management systems (eQMS) for IQI documentation should ensure compliance with FDA 21 CFR Part 11 (Electronic Records; Electronic Signatures) or EU Annex 11, as applicable. This requires audit trails, access controls, and validated electronic signatures for record approval.

Kingphar Medical — ISO 13485 Certified, Full Batch Traceability

Every Kingphar shipment includes Certificate of Analysis, batch-level sterilization records, and detailed packing lists aligned with customer purchase order specifications. Gauze, bandages, wound dressings, surgical consumables — ready for incoming inspection.

Preguntas frecuentes

Incoming Quality Inspection for Medical Consumables

What AQL level should hospitals use for incoming inspection of sterile medical consumables?

For sterile medical consumables, a risk-based AQL approach is recommended. Critical defects (compromised sterile barrier, wrong product, missing X-ray detectable marker) should use AQL 0 or 0.065% — meaning zero tolerance in most sampling plans. Major defects (dimensional non-conformance, absorbency below specification) typically use AQL 1.0%. Minor defects (cosmetic imperfections, non-critical labeling deviations) use AQL 2.5%. These values align with ISO 2859-1 and standard medical device industry practice under ISO 13485.

Is incoming quality inspection required by ISO 13485?

Yes. ISO 13485:2016 Clause 7.4.3 requires organizations to establish and implement inspection or other activities to ensure purchased product meets specified requirements. The standard requires documented procedures, defined acceptance criteria, and records of verification results. For medical device manufacturers and distributors, incoming inspection is a mandatory element of the quality management system.

What should be checked during incoming inspection of medical gauze?

Medical gauze incoming inspection should verify: mesh count (threads per inch) per purchase specification; ply count; dimensions within tolerance; absorbency per EN 14079 or USP requirements; linting level; packaging integrity with no tears, moisture, or seal breaches; lot number and expiry date legibility; and for sterile products, chemical indicator confirmation of proper sterilization processing.

How should non-conforming medical consumables be handled at receiving?

Non-conforming products should be immediately quarantined in a labeled hold area. Issue a Non-Conformance Report (NCR) with defect details and photographic evidence. Classify defect severity. Notify the supplier within 48 hours and request a CAPA response within 10–15 business days. Determine disposition — return, use-as-is (minor only, with documented justification), rework, or scrap. Track the CAPA to closure and update supplier quality scorecards.

What is the difference between supplier audit and incoming quality inspection?

A supplier audit evaluates the manufacturer's quality system, production processes, and facility capabilities — assessing the ability to consistently produce conforming products. Incoming quality inspection evaluates the actual delivered products against purchase specifications at the buyer's facility. Both are required under ISO 13485: supplier audits under Clause 7.4.1, incoming inspection under Clause 7.4.3. They are complementary, not interchangeable.

Artículos Relacionados

Continue Reading